{Reference Type}: Journal Article
{Title}: The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
{Author}: Gozes I;
{Journal}: Biol Chem
{Volume}: 397
{Issue}: 3
{Year}: Mar 2016
{Factor}: 4.7
{DOI}: 10.1515/hsz-2015-0152
{Abstract}: Fifteen years ago we discovered activity-dependent neuroprotective protein (ADNP), and showed that it is essential for brain formation/function. Our protein interaction studies identified ADNP as a member of the chromatin remodeling complex, SWI/SNF also associated with alternative splicing of tau and prediction of tauopathy. Recently, we have identified cytoplasmic ADNP interactions with the autophagy regulating microtubule-associated protein 1 light chain 3 (LC3) and with microtubule end-binding (EB) proteins. The ADNP-EB-binding SIP domain is shared with the ADNP snippet drug candidate, NAPVSIPQ termed NAP (davunetide). Thus, we identified a precise target for ADNP/NAP (davunetide) neuroprotection toward improved drug development.